SCHEMBL3091840

SCHEMBL3091840

CCc1ccc(CC2[C](Cl)N(C)c3ccccc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.40
ACHE P22303 2/20 0.35
ALOX5 P09917 1/20 0.34
TP53 P04637 1/20 0.34
NPSR1 Q6W5P4 2/20 0.34
MAPT P10636 2/20 0.34
LMNA P02545 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
HTT P42858 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
GAA P10253 1/20 0.33
THRB P10828 1/20 0.33
RECQL P46063 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HDAC4 P56524 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3085394 0.84 EGFR (0.41) EGFRACHETP53NPSR1MAPT
SCHEMBL31613810 0.75 EGFR (0.50) EGFRACHENPSR1MEN1KMT2A
SCHEMBL5667766 0.75 EGFR (0.50) EGFRACHENPSR1MEN1KMT2A
SCHEMBL13489152 0.74 EGFR (0.49) EGFRACHENPSR1MEN1KMT2A
SCHEMBL3092190 0.68 KMT2A (0.37) TP53NPSR1MAPTMEN1KMT2A
SCHEMBL9719345 0.66 ROCK2 (0.51) EGFRALOX5TP53NPSR1LMNA
SCHEMBL29206307 0.65 MGLL (0.48) TP53MAPTLMNAALDH1A1NPC1
SCHEMBL6997095 0.64 HTR2A (0.54) EGFRACHEHDAC4HDAC7HDAC5
SCHEMBL24664741 0.64 ALDH1A1 (0.65) EGFRNPSR1MAPTLMNAMEN1
SCHEMBL31092662 0.63 SMN1; SMN2 (0.48) MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207134-B2 Fused ring spiroketal derivative and use thereof as anti-diabetic drug CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-26 US disclosed
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-09-16 US disclosed
EP-2048152-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG REN, WNK1, GCKR EGFR 2076/4885ACHE 3474/4885ALOX5 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.